Global Improvement and Patient Satisfaction: Results from a Long-Term, Open-Label, Rollover Study of Valbenazine in Tardive Dyskinesia

被引：0
|
作者：
Lessig, S.
Marder, S.
Verghese, C.
Burke, J.
Jimenez, R.
Siegert, S.
Liang, G.
机构：
来源：
MOVEMENT DISORDERS | 2018年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
92
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [31] Patient Satisfaction with MAP0004: Results of an Optional Survey during a Long-Term Open-Label Safety Study
    Aurora, S.
    Buse, D.
    Lu, B.
    Kellerman, D.
    Cooper, W.
    Kori, S.
    CEPHALALGIA, 2013, 33 (S8) : 36 - 37
  • [32] Long-Term Outcomes with Valbenazine 40 mg/day in Adults with Tardive Dyskinesia
    Marder, S.
    Comella, C.
    Singer, C.
    Chepke, C.
    Burke, J.
    Farahmand, K.
    Siegert, S.
    MOVEMENT DISORDERS, 2019, 34 : S598 - S598
  • [33] Efficacy of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of a Long-Term Study (KINECT 3 Extension)
    Factor, Stewart
    Comella, Cynthia
    Correll, Christoph
    Liang, Grace
    Burke, Joshua
    O'Brien, Christopher
    NEUROLOGY, 2017, 88
  • [34] TARDIVE-DYSKINESIA AND THE LONG-TERM PATIENT
    SCHWARTZ, HJ
    HOSPITAL AND COMMUNITY PSYCHIATRY, 1979, 30 (07): : 465 - 467
  • [35] Kinect 4: A Phase 3, One-Year, Open-Label Trial of Valbenazine in Participants With Tardive Dyskinesia
    Marder, Stephen
    Kane, John
    Factor, Stewart
    Jimenez, Roland
    Thai-Cuarto, Dao
    Liang, Grace
    NEUROPSYCHOPHARMACOLOGY, 2017, 42 : S396 - S397
  • [36] Sustained Improvements in Chorea Associated With Huntington Disease With Once-Daily Valbenazine: Interim Results From a Long-Term Open-Label Study
    Stimming, Erin Furr
    Claassen, Daniel O.
    Kayson, Elise
    Goldstein, Jody
    Hinton, Sean C.
    Klepitskaya, Olga
    Zhang, Hui
    Liang, Grace
    Sheth, Bijal
    Haubenberger, Dietrich
    NEUROPSYCHOPHARMACOLOGY, 2023, 48 : 296 - 296
  • [37] Safety of long-term use of linezolid: results of an open-label study
    Vazquez, Jose A.
    Arnold, Anthony C.
    Swanson, Robert N.
    Biswas, Pinaki
    Bassetti, Matteo
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 1347 - 1354
  • [38] EFFICACY AND SAFETY OF VALBENAZINE (NBI-98854) IN SUBJECTS WITH TARDIVE DYSKINESIA: RESULTS OF A LONG-TERM STUDY (KINECT 3 EXTENSION)
    Siegert, S.
    Factor, S.
    Liang, G.
    Burke, J.
    PARKINSONISM & RELATED DISORDERS, 2018, 46 : E35 - E35
  • [39] Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study
    Hauser, Robert A.
    Barkay, Hadas
    Fernandez, Hubert H.
    Factor, Stewart A.
    Jimenez-Shahed, Joohi
    Gross, Nicholas
    Marinelli, Leslie
    Wilhelm, Amanda
    Alexander, Jessica
    Gordon, Mark Forrest
    Savola, Juha-Matti
    Anderson, Karen E.
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [40] Long-Term Outcomes in Patients with Tardive Dyskinesia who Were Early Responders with Valbenazine
    Factor, S.
    Comella, C.
    Marder, S.
    Burke, J.
    Farahmand, K.
    Siegert, S.
    MOVEMENT DISORDERS, 2019, 34 : S595 - S596
12345